Printed from Voxsanity (voxsanity.com.au) — NCT07239622 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
NCT07239622
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to take part and have signed a written consent form agreeing to participate.
- People aged between 18 and 75 years who have been diagnosed through a tissue biopsy with ovarian clear cell carcinoma that has come back or has not gone away after treatment.
- People who have already received at least one round of chemotherapy that included a platinum-based drug.
- People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (ECOG score of 0–2).
- People whose doctors expect them to live for more than 12 weeks.
- People who have measurable tumour areas that meet specific size requirements: each tumour area must be at least 10 mm at its longest point on a CT scan, MRI, or physical examination; tumour areas measured by chest X-ray must be at least 20 mm; and any affected lymph nodes must measure at least 15 mm across their short side on CT or MRI.
- People for whom at least 4 weeks have passed since their last cancer treatment.
- People whose blood counts, liver, kidney, thyroid, and heart enzyme test results are all within normal ranges.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose ovarian cancer is a type other than clear cell (a different subtype of ovarian carcinoma).
- People who have previously been treated with certain immune-based therapies known as checkpoint inhibitors (including PD-1, PD-L1, or CTLA-4 inhibitors).
- People for whom one of the study drugs (anlotinib) is not considered safe, including those with a history of a hole forming in the gut wall, surgery within 28 days before starting combination treatment or wounds that have not healed, serious bleeding or recent coughing up of blood, or any other reason the study doctor considers anlotinib unsuitable.
- People with a known allergy to any of the three study drugs: irinotecan, anlotinib, or sintilimab.
- People who have brain tumours that require surgery.
- People who have been diagnosed with another cancer in the past 5 years.
- People who have had an active autoimmune disease (where the immune system attacks the body) within the past 2 years.
- People who have received any vaccine within 1 month before joining the study.
- People who have had a blood or platelet transfusion within 4 weeks before the first dose.
- People who have taken steroid tablets or injections (not including creams, inhalers, or nasal sprays) or other medicines that suppress the immune system (such as cyclophosphamide, azathioprine, methotrexate, thalidomide, or anti-TNF drugs) within 7 days before the first dose.
- People who have used certain anti-cancer traditional Chinese medicines or immune-boosting agents (such as thymosin, interferon, or interleukin) within 2 weeks before the first dose, except when used locally to manage fluid around the lungs.
- People who have taken aspirin at doses above 325 mg per day, or other anti-inflammatory pain medicines known to affect platelet function, for 10 days in a row within the 10 days before the first dose.
- People who have been on full-dose blood-thinning or clot-dissolving medication continuously for 10 days within the 10 days before the first dose.
- People with an inherited tendency to bleed or a clotting disorder; a history of high blood pressure with blood clots; tumour growth into major blood vessels; or signs on scans suggesting a risk of bleeding, as assessed by the study doctor or a radiologist.
- People who have serious wounds, ulcers, or bone fractures that have not healed.
- People who have had an organ transplant from another person (except a corneal transplant) or a bone marrow/stem cell transplant from another person.
- People with a known diagnosis of HIV infection (confirmed by a positive HIV antibody test).
- People with untreated active hepatitis B infection (defined as testing positive for HBsAg with detectable hepatitis B virus in the blood).
- People who still have side effects rated as moderate or severe (Grade 2 or higher) from a previous cancer treatment, except for hair loss, nerve-related symptoms, low lymphocyte counts, or skin colour changes.
- People with serious or uncontrolled ongoing illness.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Principal Investigator: Huaiwu Lu, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phone: 02081332587
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
31 December 2028
Primary endpoints
Objective Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.